NANOVIBRONIX UROSHIELD INCREASES ANTIBIOTIC EFFICACY
Infections caused as a result of biofilm formation are characterized by particularly strong antibiotic and immune resistance patterns.
The goal – To explore the potential of NanoVibronix technology on increasing antibiotic efficacy and reduce biofilm formation.
- Tested products:
- Three bacterial strains were tested
- Pseudomonas Aeruginosa
- Staphylococcus Epidermidis.
- Escherichia Coli
- Biofilm formation in a closed system
A urinary catheter segment was attached to a large reservoir that contained TSB+0.2% Casamino acids medium growth. A peristaltic pump was used to create flow condition within the system.
The catheter segment was inoculated with a 0.15×109 bacterial culture in the logarithmic phase. The system was incubated for 48h in 37oC with medium flow of 10ml/h.
- 24h following bacterial inoculation, the UroShield device was attached to the urinary catheter segment and the device was activated for 72h with or without the desired antibiotic.
The effect of UroShield on biofilm formation
Following a treatment with UroShield, less bacterial attachment to the urinary catheter was observed. Reductions of 100%, 74%, 97% and 98% in the number of bacterial colonies were observed when the UroShield treatment was applied to the flow system with initial bacterial concentrations of 101, 102, 103, and 104, respectively. No reduction was observed when using the UroShield treatment with initial bacterial concentration of 108 cells/ml.
The results suggest that using Nanovibronix technology reduces the potential of bacterial attachment to the catheter surface thus reduce the amount of biofilm formation.
The effect of UroShield on antibiotic efficacy in treating biofilm
When the biofilm was treated by Gentamycin with the UroShield, the effect of Gentamycin was increase by approx. 89%, 95% and 90% when treating biofilm from P. aeroginosa, E. coli and S. Epidermidis, respectively, in comparison to antibiotic treatment only.
The results indicate that when using the UroShield device, Gentamycin concentration may be substantially reduced for effective treatment the biofilm.
UroShield application to urinary catheters provides a twofold benefit. Prevention of bacterial adhesion to the catheter lumen on one hand and substantially decreasing antibiotic required dosage for effective treatment of biofilm on the other.
Combining UroShield technology with significant lower dose of antibiotics will allow better treatment for the patient by delaying the development of resistant bacterial strain, while reducing nosocomial UTI events and related economical burden on the health care providers.